Palbonix (Palbociclib) 100 MG – 21 Capsules

Uses of Palbonix (Palbociclib) 100 MG –

• Breast cancer

Side effects of Palbonix (Palbociclib) 100 MG –

• Fatigue
• Hair loss
• Rash
• Vomiting
• Diarrhea
• Nausea
• Decreased blood cells (red cells, white cells, and platelets)
• Infection
• Decreased appetite
• Fever

How to use Palbonix 100 MG –

Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Palbonix 100 is to be taken with food.

How Palbonix 100 MG works –

Palbonix 100 is an anti-cancer medication. Cyclin-dependent kinase 4 and 6 (chemical messengers) are downstream of signaling pathways that lead to the proliferation of cells. This medicine works by inhibiting cyclin-dependent kinase 4 and 6, thus arresting the cancer cell cycle (cell growing process). It also targets the estrogen (hormone) receptor-positive breast cancer cells by disrupting the cell cycle.

Indication

Indicated for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, or with fulvestrant in women with disease progression endocrine therapy

Administration

Hard Capsule: Should be taken with food. Take at the same time each day. Swallow whole, do not chew/crush/open. Avoid grapefruit products.

Adult Dose

Oral Hormone receptor-positive, HER2-negative locally advanced carcinoma of the breast, Hormone receptor-positive, HER2-negative metastatic carcinoma of breast Adult: In combination with an aromatase inhibitor, or in combination with fulvestrant in women who have received prior endocrine therapy: 125 mg once daily for 21 days, followed by 7 days off, repeat every 28 days until disease progression or unacceptable toxicity. Dosage Modifications Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guidelines). Recommended dose reduction: 1st reduction: 100 mg once daily; 2nd reduction: 75 mg once daily; discontinue if dose reduction below 75 mg once daily is required. Hepatic impairment Mild or moderate (Child-Pugh A or B): No dose adjustment required. Severe (Child-Pugh C): Reduce dose to 75 mg/day for Days 1-21 of each 28-day cycle

Renal Dose

Renal impairment Mild, moderate, or severe (CrCl >15 mL/min): No dose adjustment required. Hemodialysis: Not studied.

Contraindication

Pregnancy and lactation.

Mode of Action

Palbociclib is a reversible, selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Cyclin D1, CDK 4, and 6 are downstream of multiple signaling pathways which lead to cellular proliferation. Inhibition of CDK4/6 reduces the proliferation of breast cancer cell lines by blocking progression from G1 into the S phase of the cell cycle.

Precaution

Neutropenia was observed in clinical trials; febrile neutropenia was also reported; monitor CBC count before starting the drug and at the beginning of each cycle, as well as on Day 14 of the first 2 cycles, and as clinically indicated; dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop grade 3 or 4 neutropenia.

Side Effect

The most common adverse reactions are:

• Nausea
• Vomiting
• Loss of appetite
• Diarrhea
• Tiredness
• Weakness
• Hair loss
• Mouth sores
• Numbness/tingling of arms/legs.

***The above information comes from the Internet. Please consult with a doctor for medical advice.

See more breast cancer-related medicine HERE